{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:41:30Z","timestamp":1790628090960,"version":"4.1.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"This study beneficiated from financial support granted by the mutual insurance compagny EOVI: https:\/\/www.eovi-mcd.fr\/. Grant number : AP-EOV-18-002."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Atten Disord"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>Objective: Prevalence estimates for ADHD have been debated for decades. In France, the only available study states the prevalence rate in France ranges from 3.5% to 5.6% of children aged 6 to 12. It also evaluates that 3.48% of children aged 6 to 12 are treated with psychostimulants. The article uses a different method to determine whether these estimates hold true. Method: Estimating ADHD diagnosis and methylphenidate prescription rates can be done by analyzing national health care insurance system\u2019s data. We used data from the French Healthcare Insurance as reported by the National Agency for Medicines and Health Products Safety. Results: We claim that an adequate estimate of the ADHD prevalence rate in France fluctuates around 0.3% of children aged 6 to 11. Discussion: Methodological biases in ADHD prevalence studies and factors contributing to the low level of prescription in France need to be assessed. Conclusion: We call for supplementary investigations in health care insurance databases to conduct contradictory studies.<\/jats:p>","DOI":"10.1177\/1087054720905664","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T06:13:24Z","timestamp":1581920004000},"page":"1347-1350","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["ADHD Diagnosis and Drug Use Estimates in France: A Case for Using Health Care Insurance Data"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-9198","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Ponnou","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Rouen, Mont-Saint-Aignan, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9lo\u00efse","family":"Haliday","sequence":"additional","affiliation":[{"name":"Paris Nanterre University, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"bibr1-1087054720905664","unstructured":"National Agency for Medicines and Health Products Safety. (2017). M\u00e9thylph\u00e9nidate: donn\u00e9es d\u2019utilisation et de s\u00e9curit\u00e9 d\u2019emploi en France. https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Methylphenidate-donnees-d-utilisation-et-de-securite-d-emploi-en-France-Point-d-Information"},{"key":"bibr2-1087054720905664","volume-title":"Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment","author":"Barkley R. A.","year":"2005","edition":"3"},{"key":"bibr3-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1002\/1520-6807(199310)30:4<338::AID-PITS2310300408>3.0.CO;2-S"},{"key":"bibr4-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1177\/1087054705280413"},{"key":"bibr5-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1007\/BF01876136"},{"key":"bibr6-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2008.09.010"},{"key":"bibr7-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044275"},{"key":"bibr8-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1177\/1087054705278762"},{"key":"bibr9-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1177\/000992280204100702"},{"key":"bibr10-1087054720905664","doi-asserted-by":"crossref","unstructured":"Lecendreux M., Konofal E., Faraone S. V. (2011). Prevalence of attention deficit hyperactivity disorder and associated features among children in France. Journal of Attention Disorders, 15(6), 516\u2013524. https:\/\/doi.org\/10.1177\/1087054710372491","DOI":"10.1177\/1087054710372491"},{"key":"bibr11-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1002\/pits.10000"},{"key":"bibr12-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.05.005"},{"key":"bibr13-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.12.1793"},{"key":"bibr14-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.6.942"},{"key":"bibr15-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyt261"},{"key":"bibr16-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1177\/1087054707300094"},{"key":"bibr17-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2019.112492"},{"key":"bibr18-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1542\/peds.103.3.e38"},{"key":"bibr19-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1080\/87565641.2013.783833"},{"key":"bibr20-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1097\/00004703-199806000-00003"},{"key":"bibr21-1087054720905664","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199603000-00013"},{"key":"bibr22-1087054720905664","doi-asserted-by":"crossref","unstructured":"Yoshida M., Obara T., Kikuchi S., Satoh M., Morikawa Y., Ooba N., Yamaguchi H., Mano N. (2020). Drug prescriptions for children with ADHD in Japan: A study based on health insurance claims data between 2005 and 2015. Journal of Attention Disorders, 24(2), 175\u2013191. https:\/\/doi.org\/10.1177\/1087054719843179","DOI":"10.1177\/1087054719843179"},{"key":"bibr23-1087054720905664","doi-asserted-by":"crossref","unstructured":"Zhou Z., Betts K. A., Bocharova I., Kinrich D., Spalding W. M. (2020). Concomitant use of psychotropic medication with stimulants for the treatment of ADHD in children and adolescents: A retrospective insurance claims study in the United States. Journal of Attention Disorders, 24(2), 336\u2013347. https:\/\/doi.org\/10.1177\/1087054718784668","DOI":"10.1177\/1087054718784668"}],"container-title":["Journal of Attention Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1087054720905664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1087054720905664","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1087054720905664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:28:02Z","timestamp":1777490882000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1087054720905664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1177\/1087054720905664"],"URL":"https:\/\/doi.org\/10.1177\/1087054720905664","relation":{},"ISSN":["1087-0547","1557-1246"],"issn-type":[{"value":"1087-0547","type":"print"},{"value":"1557-1246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]}}}